Phase II study of recombinant alpha-interferon in malignant melanoma.

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.

Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.

A phase II investigation of pentostatin in metastatic malignant melanoma.

A phase I-II study of recombinant intrapleural alpha interferon in malignant pleural effusions.

Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.

A phase II study of taxol in patients with malignant melanoma.

Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma.

II study.

Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.

Phase II study of tauromustine in malignant glioma.

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.

Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.

Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.

Intravenous carboplatin for recurrent malignant glioma: a phase II study.

Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group.

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.

Phase II trial of vorinostat in advanced melanoma.

Phase II trial of carboplatin in patients with advanced melanoma.

[Malignant melanoma of the conjunctiva: histopathologic study].

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.

Suggest Documents

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.

Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.

A phase II investigation of pentostatin in metastatic malignant melanoma.

A phase I-II study of recombinant intrapleural alpha interferon in malignant pleural effusions.

Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.

A phase II study of taxol in patients with malignant melanoma.

Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma.

II study.

Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.

Phase II study of tauromustine in malignant glioma.

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.

Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.

Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.

Intravenous carboplatin for recurrent malignant glioma: a phase II study.

Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group.

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.

Phase II trial of vorinostat in advanced melanoma.

Phase II trial of carboplatin in patients with advanced melanoma.

[Malignant melanoma of the conjunctiva: histopathologic study].

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.

Phase II study of recombinant alpha-interferon in malignant melanoma.

Recommend Documents

Follow Us